Free Trial

Motus GI Q1 2023 Earnings Report

Motus GI logo
$0.0001 0.00 (-50.00%)
(As of 12/20/2024 03:04 PM ET)

Motus GI EPS Results

Actual EPS
-$9.75
Consensus EPS
-$15.90
Beat/Miss
Beat by +$6.15
One Year Ago EPS
N/A

Motus GI Revenue Results

Actual Revenue
$0.06 million
Expected Revenue
$0.50 million
Beat/Miss
Missed by -$440.00 thousand
YoY Revenue Growth
N/A

Motus GI Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.

Motus GI Earnings Headlines

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis
Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.
See More Motus GI Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Motus GI? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Motus GI and other key companies, straight to your email.

About Motus GI

Motus GI (NASDAQ:MOTS) operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.

View Motus GI Profile

More Earnings Resources from MarketBeat

Upcoming Earnings